Abstract
Introduction
Di abetes therapy is currently at a turning point, indicative of recent technical and commercial advances. 1 Despite the fact that finger-stick blood glucose sensing will remain the method of choice for the majority of people with diabetes in the coming years, short-term sensors for interstitial glucose monitoring in type I and II diabetes have been gaining significant momentum and will surely gain wider acceptance levels. 2 However, their success will ultimately depend on various factors related to the functionality and reliability of commercially available glucose monitoring systems. For example, the continuous glucose monitoring system (CGMS) System Gold from MiniMed/Medtronic and the short-term sensor (STS) from Dexcom, along with the FreeStyle Navigator continuous glucose monitor by Therasense/Abbott (Food and Drug Administration approval pending), are the most advanced sensor systems to date. [3] [4] [5] [6] All three systems are based on a disposable electroenzymatic sensing platform, relying on the amperometric detection of glucose by glucose oxidase immobilized to an electrode. Both the MiniMed/Medtronic CGMS and the STS Dexcom sensor require several calibrations per day for reliable blood glucose detection. More importantly, both sensors require up to a 2-hour warm-up period immediately after implantation or, in the case of the MiniMed/Medtronic CGMS sensor, when the sensor is reconnected to the readout unit (e.g., after bathing). It remains to be seen how these devices will be accepted if they require extended warm-up periods, frequent "finger stick" calibrations, and/or if their performance is unreliable because of shifts in sensor sensitivity.
Over the last several years, research into fluorescence affinity sensors (FAS) for glucose detection has steadily gained acceptance among scientists and clinicians through the introduction of a number of improved glucosesensitive assays based on either glucose-specific protein concanavalin A (Con A) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] or borate-based artificial glucose-specific receptors. 23, 24 Independent of the type of receptor, there are several intrinsic advantages of a fluorescence affinity sensor over electrode-enzymatic sensors in terms of practicality for in vivo sensing. For one, the light-based signal detection system does not suffer from the need for warm-up time when the sensor is disconnected from the readout unit, as the light-based signal is immediately available for glucose determination. Second, the absence of an electrode-based system eliminates potential interferences of electrode-active components that may enter interstitial fluid (ISF), such as acetaminophens. Third, the nature of affine interactions in receptor-based sensors eliminates the occurrence of "autodestructive" side products, e.g., hydrogen peroxide, as produced by electroenzymatic sensors. Last but not least, the binding reaction in affinity-based sensors is equilibrium driven, resulting in a signal sensitivity that is independent on the rate of glucose diffusion into the sensor. This is an advantage when compared to electroenzymatic sensors, which are consumptive and, hence, their signal is rate dependent.
Since 2002 our group has made fast and steady progress toward improvements and optimization of a Con A-based fluorescence affinity sensor for in vivo glucose monitoring. 25, 26 To briefly review our progress, which we have reported previously, 25 we demonstrated significant improvements in the chemical stability of the FAS over earlier Con A-based sensors by immobilizing Con A to a macroporous hydrogel, such as Sepharose, which eliminates precipitation of Con A and increased in vitro functionality of the FAS over a time period from 3 to 6 months at 37°C. The thermostability of bare Con A Sepharose at 37°C was maintained over 450 days with only 20% loss of activity. In addition to our research on studying a transdermal FAS for longterm glucose monitoring in type I and II diabetes, 26 we have been concentrating our interest on developing a fiber-coupled FAS for short-term (3-5 days) interstitial glucose monitoring. The basic design of this prototype sensor is facilitated by interrogating a hollow dialysis fiber containing the fluorescent Con A-based assay with an optical fiber (see Figure 1) . This concept was first described by Schultz and co-workers, 7 who demonstrated measurement of blood sugar in the jugular vein of a dog. However, their sensor chemistry was ill-suited for longer in vivo interrogation as a consequence of strong photobleaching of fluorescent dyes (fluorescein-dextran) and elaborate and inferior assay chemistry. In contrast, we have employed much brighter and more photostable dyes (Alexa 647 and Alexa 750), enabling us to detect fluorescence with off-the-shelf photodetectors instead of cumbersome and power-consuming photomultipliers. Figure 2 illustrates the mechanism of fluorescence signal generation in the sensor. The absorption spectrum of the acceptor chromophore overlaps with the fluorescence emission spectrum of the donor. When the donor dye bound to the glucose analogue (dextran) is in proximity to the acceptor dye attached to immobilized Con A, the fluorescence decreases because of fluorescence resonance energy transfer (FRET) (see Figures 2A and 2B. ) Upon diffusion of fluorescent dextran from the Con A after competitive displacement by glucose, an increase in fluorescence is observed (see Figures 2C and 2D) . The signal ratio of FRET-based glucose-sensitive fluorescence to the reference dye provides a light-intensity independent sensor output.
This article assesses the feasibility of using the fibercoupled FAS for 3-day glucose monitoring in in vivo experiments in small and large animal models.
Materials and Methods

Preparation of FAS Assay Suspension
The procedure was described in another paper. 25 Briefly, Alexa 750 succinimidyl ester (Invitrogen, Carlsbad, CA) was conjugated to Con A Sepharose (GE Bioscience). Alexa 647 succinimidyl ester (Invitrogen) was conjugated to 70,000 Da amino-dextran (Invitrogen). Conjugation reactions were performed according to the supplier's protocol. The conjugation buffer was 12 mM phosphate- Figure 1 . Conceptual illustration of a fiber-coupled fluorescence affinity sensor (FAS). The actual sensor device, which is attached to the distal tip of an optical fiber, resides in the subdermal tissue that is filled with interstitial fluid and is well vascularized. A hollow fiber made of a cellulose acetate membrane provides a housing that allows glucose to diffuse through but prevents Con A, dextran, or beads from leaking out of the sensor. The presence of glucose leads to an increase in sensor fluorescence, which is measured by guiding laser light through the optical fiber into the sensor and measuring the fluorescence returning back through the same fiber with a linear charge-coupled device array spectrometer. Fiber-coupled Hollow Fiber Sensor Superficial Skin animal 1 to 4 cm from the midline. After the sensor and needle were pushed approximately 2 cm into the skin, the hypodermic needle was entirely withdrawn, leaving the sensor exposed to skin tissue. A MiniMed/Medtronic CGMS sensor (Northridge, CA) was coimplanted in each rat for comparison purposes. After one hour of baseline acquisition by the implanted FAS, "regular" fast-acting insulin (0.5 unit/kg) was administered subcutaneously. After another hour, a bolus glucose injection (50% dextrose, 3 ml/kg) was given intraperitoneally (IP). Serial blood samples from the tail vein were taken approximately every 5 to 10 min over the 2-to 3-h period and measured using a FreeStyle glucometer (Abbott, IL). At the end of the experiment, blood glucose was normalized by an IP bolus injection of 50% dextrose and the animal was returned to its cage. When a 3-day experiment was performed, the sensor sites were protected with bandages and masking tape to prevent sensor rupture or removal by the animal. On day 3, an identical modified glucose tolerance test was performed. At the end of the experiment, the FAS was carefully removed from the site and the animal was returned to its cage.
FAS Implantation and Glucose Testing in Pigs
Juvenile nondiabetic farm pigs (25-30 kg) were preanesthetized with ketamine (1 ml/50 kg), scrubbed thoroughly with povidone and warm water, and then maintained with 1-4% isoflurane by mask. After a saline rinse for 10 min, up to three fiber-coupled FAS were inserted in the upper back using a hypodermic needle as described previously. We implanted four sensors for redundancy and to maximize our chances that sensors would remain in the animals. Sensors were secured with tape and covered with sterile Tegaderm bandages and masking tape when not in use. A MiniMed/ Medtronic sensor was coimplanted in each pig for comparison purposes. To modulate blood glucose, 25 ml of 50% dextrose was infused intravenously through an ear vein. Blood samples were collected from a vein in the contralateral ear. On day 3, all sensors remained implanted and one was chosen for monitoring. After the experiments on day 3, sensors were carefully removed and the pig was returned to its cage.
All animal studies were carried out at an Association for Assessment and Accreditations of Laboratory Animal Careaccredited facility and in accordance with an Institutional Animal Care and Use Committee-approved protocol.
Analysis of in Vivo FAS Response
Both the glucose-sensitive emission at 675 nm and the reference dye emission at 780 nm were recorded buffered saline solution (pH 7.1, 0.9% NaCl, 1 mM CaCl 2 ) without NaN 3 . To make a sensor suspension, Alexa 647 dextran was then mixed with Alexa 750 Con A Sepharose at a final concentration of 1 to 2 mg/ml and stored in the dark at 4°C.
Manufacture of Fiber-Coupled FAS
One end of a 175-µm-diameter multimode polymer optical fiber (POF) was mechanically spliced to two 105-µm-diameter silica optical fibers. The proximal ends of the two smaller fibers were terminated with SMA-905 connectors. One of the fibers was attached to a collimated laser diode at 650 nm (Thorlabs, Newton, NJ) and the other was attached to a miniature spectrometer (USB-2000, Ocean Optics, Dunedin, FL). An individual hollow dialysis fiber (diameter 210 µm, length 5 mm) was carefully pushed onto the end of the 175-µm POF. The hollow fiber was then filled with sensing suspension by aspiration and sealed with cyanoacrylate (Loctite) at both ends. An additional bonding sleeve made of thin-walled polyimide tubing was then attached over the junction between the optical fiber and the sensor fiber. A microphotograph of the FAS tip is shown in Figure 3 . The entire fiber sensor assembly fits inside a 20-gauge hypodermic needle for insertion into skin tissue. 
FAS Implantation and Testing in Hairless Rats
Nondiabetic male hairless rats of approximately 300 g were anesthetized and maintained with isoflurane by inhalation. Before implantation the sensors were bathed for 10 min in sterile saline. A 20-gauge hypodermic needle containing the fiber-coupled FAS was inserted intradermally at a shallow angle on the dorsum of the simultaneously with a rate of 10-15 measurements h -1 and stored on a notebook computer. After each experiment, the 675-and 780-nm signals were analyzed for drift due to photobleaching and normalized accordingly. Normalization was performed by determining the slope of the change in emission at 675 and 780 nm, respectively, before and after the experiment (usually 3-4 hours) at the same glucose concentration. Then the corrected ratio signal was calculated. Glucose concentrations measured by FAS were determined retrospectively. The initial baseline period during which no changes in blood glucose were measured (usually 50 to 60 min) was used for one-point blood glucose calibration. If the one-point glucose calibration reading was not in agreement with the in vitro calibration curve for FAS obtained 24 hours before the in vivo experiment, the calibration curve was shifted along the y axis accordingly with the slope remaining constant. The correlation coefficient R, describing the linear relationship between venous blood glucose and FAS signal, was calculated by minimizing the lag time between venous blood glucose and FAS output. MiniMed/Medtronic CGMS data were extracted from MiniMed Solutions CGMS software (MMT-7310; version 3.0B) into Windows XP Excel by a Matlab application (version 4.2c.1, The MathWorks, Inc., Natick, MA).
Results
Operational in Vitro Stability of Fiber-Coupled FAS
In order to validate stable performance of the prototype fiber-coupled FAS over several days, we measured the fluorescence response during random glucose concentrations cycling at 37°C over a period of 3 days. Figure 4A shows the ratio response measured at the same glucose concentration over 3 days. The corresponding calibration curve shown in Figure 4B has a linear slope ranging from 0 to 540 mg/dl glucose and a correlation coefficient of 0.99. The sensor showed excellent signal stability during the test period. The day-to-day variation of the ratio signal did not exceed 3%. 
Acute and Chronic in Vivo Response of Fiber-Coupled FAS in Small Animal Model
Results of four independent animal experiments in anesthetized hairless rats are shown in Figure 5 . Figures 5A and 5B show the performance of two fiber-coupled FAS in two different rats, while Figures 5C and 5D depict the results of two sensors implanted in the same rat. A functional delay associated with a one-hour warm-up period of the MiniMed/Medtronics CGMS is evident in Figures 5A and 5B. However, in Figures 5C and 5D , implantation of the fiber-coupled sensor overlapped with the end of the CGMS warm-up phase. As can be seen in Figures 5A and 5B, the fiber-coupled sensor required less than 60 min of equilibration time after implantation to reach operational functionality. Overall, the ratio response of our prototype FAS correlated very well with changes in blood glucose levels. The correlation coefficients ranged from 0.88 to 0.94 with minimal lag times of less than 5 min.
For an animal carrying the FAS for 3 days, the response is shown in Figure 6 . The correlation coefficients of 0.94 and 0.81 on days 1 and 3, respectively, indicate good stability of the FAS over the test period. The slightly lower correlation coefficient on day 3 was probably due to excessive movement of the implanted sensor by the highly agile animals, which might have led to bending of the flexible FAS sensor chamber relative to the field of view of the optical fiber or perhaps even causing microruptures at the membrane/sealant interface, which may allow material to leak out of the sensing chamber. This, in conjunction with an increase in trauma, might have possibly resulted in attenuation in sensitivity of the sensor.
Acute and Chronic in Vivo Performance of FAS in Large Animal Model
Results of acute implantation and blood glucose tolerance tests of two sensors implanted in two different pigs are shown in Figure 7 . Approximately one hour after implantation, a bolus injection of dextrose was given via the ear vein, resulting in the large spike in measured blood sugar. In both animals the FAS responded after a short delay (less than 15 min) with an increase in the ratio signal. In the second animal ( Figure 7B ), a second bolus injection of dextrose was given to the animal at 100 min, upon which the FAS responded almost immediately with a delay of 5 min. Because glucose was administered intravenously rather than intraperitoneally in pig experiments, it is not surprising that the interstitially implanted FAS and CGMS sensors showed a dampened response, as the rate of clearance of glucose from blood by the liver may be higher than the rate of glucose diffusion from blood into ISF. However, the experiments showed acceptable correlation of the FAS response with blood glucose changes during the initial period after implantation. Figure 8 shows results of one sensor during a 3-day implantation experiment. The correlation coefficients of 0.89 and 0.88 for days 1 and 3, respectively, demonstrate good stability of the sensor response over the target period of 3 days. Sensors were generally well tolerated by the animals. Visual assessment of one implantation site after explantation on day 3 showed only slight redness at the insertion site (see Figure 9) , which subsided after a few days, possibly the result of minor bleeding after FAS insertion on day 1. No evidence of inflammation, irritation, or infection was observed at any of the implantation sites.
Discussion
The objective of this study was to demonstrate feasibility of a fiber-coupled FAS for glucose monitoring over several days in small and large animal models. In general, the stability of the FAS response obtained in vitro over 3 days in prior studies was confirmed in in vivo studies in rats and pigs. Implanted FAS exhibited good overall correlation with blood sugar manipulations. It is relevant to mention that the successful operation of FAS in pigs is significant, as the pig model is similar to humans in terms of skin anatomy and general physiology. The shift from small animal model to large animal model also improved the rate of success of in vivo experiments, as the sensor was much less susceptible to destruction by the animal when implanted in a pig (back). This will enable us to perform ambulatory experiments to assess the accuracy of our device during longer periods of continuous glucose monitoring. Our in vivo studies demonstrated fast equilibration of the FAS response after implantation. We found that it took on average not more than 60 min and, in some cases, less than 30 min before the sensor signal adjusted to the baseline blood glucose level. These results can be corroborated with results from a study performed with an implanted viscometric affinity sensor with a similar short equilibration time after implantation in humans. 28 This is in noticeable difference to reports of electroenzymatic sensors, which require 1-3 hours of warm-up time or even more due to the need of the enzyme electrode to electrically equilibrate with the ISF. The absence of a warm-up time of the FAS was obvious on day 3 after reconnecting the sensor to the light source and readout device in the large animal experiment (see Figure 8B ) when the FAS response to glucose was in close approximation to the venous blood glucose levels. Overall, these results strengthen our hypothesis that the intrinsic nature of fluorescence affinity sensors, as explained earlier, appears to be advantageous for in vivo glucose monitoring.
The time delay of the FAS in response to blood glucose modulators was modest and did not exceed more than 10 min, even in pigs. We saw very short time lags in rats. In pigs we noticed quite often larger lag times immediately after implantation, which might be due to subacute insertion trauma or other reasons still under investigation. Surely different degrees of vascularization and relative fat content at the implantation site in the pig might have had an impact on the time response of FAS. However, lag times after 100 min of FAS implantation appeared to become progressively shorter (compare Figures 7B and 8B) , although more research is needed to confirm this finding further. These preliminary results confirm that initial trauma due to FAS implantation was minimal and that the short-term biocompatibility of the materials of the sensors was more than adequate. In two earlier publications, we also addressed safety concerns over the use of Con A. We demonstrated supportive Figure 8 . Stability of FAS response over a 3-day period in a pig. The sensor was implanted on day 1 in an anesthetized pig, and its acute response to variation in blood glucose due to injection of dextrose was measured (A). The animal was allowed to move around freely on day 2. On day 3, the sensor response was tested again (B). ♦, FAS; Δ, blood glucose. R denotes correlation coefficient between blood glucose and FAS signal. The R value of MiniMed CGMS is 0.83 (A). experimental and empirical evidence for the absence of systemic toxicity at low Con A doses injected through the subcutaneous route. 29 This study performed retrospective analysis of the sensor signal obtained in vivo. The reason for it was a drift of the sensor ratio signal as a consequence of changes in the fluorescence signal (photobleaching) caused by an excessive illumination regimen (on the average of 10 s per measurement) because of manual data acquisition with our prototype setup. Despite the good correlation of the FAS response to blood glucose, we concede that the one-point calibration model might not have been ideal, considering, for example, the discrepancy of glucose determined by FAS versus venal blood glucose (see Figure 8B) . Refining the calibration model is under current investigation. However, we believe that real-time glucose monitoring with minimal signal drift is possible by reducing laser power or shortening exposure time to less than one-tenth of a second by implementing automated signal acquisition. By implementing these options, fluorescence-based drift will be minimal during the course of 3 to 5 days, which will enable the FAS to predict blood glucose level changes in real time.
Conclusion
We evaluated the feasibility of a prototype-implantable, fiber-coupled fluorescence affinity sensor for continuous glucose monitoring by studying its acute and chronic in vivo performance in hairless rats and pigs. The time lag of the FAS measurements did not exceed 10 min even on day 3 in both animal models. Correlation coefficients of the FAS with blood glucose changes induced by blood sugar manipulations in acute and chronic studies were in the acceptable clinical range. In order to minimize the effect on signal drift of the real-time glucose monitoring FAS, we anticipate reducing light input levels per measurement. Overall, the fiber-coupled FAS performance over a 3-day period compares favorably to other continuous glucose monitoring platforms and indicates its potential value for diabetes therapy.
